LJPP Stock Overview
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
La Jolla Pharmaceutical Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.07 |
| 52 Week High | US$6.11 |
| 52 Week Low | US$2.94 |
| Beta | 2.41 |
| 1 Month Change | 1.40% |
| 3 Month Change | 73.44% |
| 1 Year Change | 93.75% |
| 3 Year Change | -33.65% |
| 5 Year Change | -75.48% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| LJPP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.6% | -3.1% | 1.8% |
| 1Y | 93.7% | -22.4% | 2.2% |
Return vs Industry: LJPP exceeded the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: LJPP exceeded the German Market which returned 5.9% over the past year.
Price Volatility
| LJPP volatility | |
|---|---|
| LJPP Average Weekly Movement | 24.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LJPP's share price has been volatile over the past 3 months.
Volatility Over Time: LJPP's weekly volatility has increased from 14% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 61 | Larry Edwards | www.lajollapharmaceutical.com |
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States.
La Jolla Pharmaceutical Company Fundamentals Summary
| LJPP fundamental statistics | |
|---|---|
| Market cap | €155.85m |
| Earnings (TTM) | €3.99m |
| Revenue (TTM) | €46.72m |
39.1x
P/E Ratio3.3x
P/S RatioIs LJPP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LJPP income statement (TTM) | |
|---|---|
| Revenue | US$46.49m |
| Cost of Revenue | US$8.87m |
| Gross Profit | US$37.62m |
| Other Expenses | US$33.65m |
| Earnings | US$3.97m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.16 |
| Gross Margin | 80.92% |
| Net Profit Margin | 8.54% |
| Debt/Equity Ratio | -179.3% |
How did LJPP perform over the long term?
See historical performance and comparison